OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
Andrew X. Zhu, Teresa Macarulla, Milind Javle, et al.
JAMA Oncology (2021) Vol. 7, Iss. 11, pp. 1669-1669
Open Access | Times Cited: 332
Andrew X. Zhu, Teresa Macarulla, Milind Javle, et al.
JAMA Oncology (2021) Vol. 7, Iss. 11, pp. 1669-1669
Open Access | Times Cited: 332
Showing 1-25 of 332 citing articles:
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, John Bridgewater, Julien Edeline, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 127-140
Open Access | Times Cited: 307
Arndt Vogel, John Bridgewater, Julien Edeline, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 127-140
Open Access | Times Cited: 307
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Demetrios Moris, Manisha Palta, Charles Kim, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 2, pp. 198-222
Open Access | Times Cited: 260
Demetrios Moris, Manisha Palta, Charles Kim, et al.
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 2, pp. 198-222
Open Access | Times Cited: 260
Gallbladder cancer
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 180
Juan Carlos Roa, Patricia García, Vinay K. Kapoor, et al.
Nature Reviews Disease Primers (2022) Vol. 8, Iss. 1
Closed Access | Times Cited: 180
Cancer epigenetics in clinical practice
Verónica Dávalos, Manel Esteller
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 4, pp. 376-424
Open Access | Times Cited: 141
Verónica Dávalos, Manel Esteller
CA A Cancer Journal for Clinicians (2022) Vol. 73, Iss. 4, pp. 376-424
Open Access | Times Cited: 141
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial
Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, et al.
The Lancet (2023) Vol. 401, Iss. 10372, pp. 195-203
Closed Access | Times Cited: 130
Kohei Nakachi, Masafumi Ikeda, Masaru Konishi, et al.
The Lancet (2023) Vol. 401, Iss. 10372, pp. 195-203
Closed Access | Times Cited: 130
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 126
Domenico Alvaro, Gregory J. Gores, Joël Walicki, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 181-208
Open Access | Times Cited: 126
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 126
Metabolic reprogramming in cholangiocarcinoma
Chiara Raggi, Maria Letizia Taddei, Colin Rae, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 849-864
Open Access | Times Cited: 97
Chiara Raggi, Maria Letizia Taddei, Colin Rae, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 849-864
Open Access | Times Cited: 97
Emerging therapies in cancer metabolism
Yi Xiao, Tian‐Jian Yu, Ying Xu, et al.
Cell Metabolism (2023) Vol. 35, Iss. 8, pp. 1283-1303
Open Access | Times Cited: 90
Yi Xiao, Tian‐Jian Yu, Ying Xu, et al.
Cell Metabolism (2023) Vol. 35, Iss. 8, pp. 1283-1303
Open Access | Times Cited: 90
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 85
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 85
Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 56-65
Closed Access | Times Cited: 84
Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon, et al.
The Lancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 56-65
Closed Access | Times Cited: 84
How I treat biliary tract cancer
Ángela Lamarca, Julien Edeline, Lipika Goyal
ESMO Open (2022) Vol. 7, Iss. 1, pp. 100378-100378
Open Access | Times Cited: 80
Ángela Lamarca, Julien Edeline, Lipika Goyal
ESMO Open (2022) Vol. 7, Iss. 1, pp. 100378-100378
Open Access | Times Cited: 80
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 79
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 79
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 692-692
Closed Access | Times Cited: 42
Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 692-692
Closed Access | Times Cited: 42
Metabolic reprogramming in the tumor microenvironment of liver cancer
Jian Lin, Dongning Rao, Mao Zhang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 35
Jian Lin, Dongning Rao, Mao Zhang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 35
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Navigating the landscape of liver cancer management: Study designs in clinical trials and clinical practice
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 18
Giuseppe Cabibbo, Ciro Celsa, Lorenza Rimassa, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 6, pp. 957-966
Open Access | Times Cited: 18
Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
Lei Tao, Yue Zhou, Yuan Luo, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 17
Lei Tao, Yue Zhou, Yuan Luo, et al.
MedComm – Oncology (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 17
“Biological R2” Resection for Intrahepatic Cholangiocarcinoma: Identification of Patients at Risk for Poor Oncologic Outcomes after Curative-Intent Resection
Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, et al.
HPB (2025)
Closed Access | Times Cited: 2
Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, et al.
HPB (2025)
Closed Access | Times Cited: 2
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Felix Krenzien, Nora Nevermann, Alina Krombholz, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 362-362
Open Access | Times Cited: 54
Felix Krenzien, Nora Nevermann, Alina Krombholz, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 362-362
Open Access | Times Cited: 54
Recent advances of IDH1 mutant inhibitor in cancer therapy
Wangqi Tian, Weitong Zhang, Yifan Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53
Wangqi Tian, Weitong Zhang, Yifan Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma
Taek Chung, Young Nyun Park
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 49
Taek Chung, Young Nyun Park
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 49
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation
Sandra J. Casak, Shan M. Pradhan, Lola A. Fashoyin-Aje, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 13, pp. 2733-2737
Open Access | Times Cited: 47
Sandra J. Casak, Shan M. Pradhan, Lola A. Fashoyin-Aje, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 13, pp. 2733-2737
Open Access | Times Cited: 47
Biology of IDH mutant cholangiocarcinoma
Meng‐Ju Wu, Lei Shi, Joshua Merritt, et al.
Hepatology (2022) Vol. 75, Iss. 5, pp. 1322-1337
Closed Access | Times Cited: 40
Meng‐Ju Wu, Lei Shi, Joshua Merritt, et al.
Hepatology (2022) Vol. 75, Iss. 5, pp. 1322-1337
Closed Access | Times Cited: 40
